FindTrial
Sign In

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Motion Delos: An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06138613
Enrollment
705
Registered
2023-11-18
Start date
2023-02-27
Completion date
2027-12-30
Last updated
2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motion Sickness

Brief summary

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

Detailed description

This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness.

Interventions

DRUGTradipitant

Oral Capsule

Sponsors

Vanda Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* History of Motion Sickness * Age 18-75

Exclusion criteria

* Nausea-inducing disorder other than motion sickness * BMI \> 40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Design outcomes

Primary

MeasureTime frameDescription
Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).through study completion, approximately 1 yearSafety will be monitored using clinical measures, vital signs, blood chemistry, hematology, urology, and ECGs.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026